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Relatively little information is available on the incidence of secondary cancer in non-Hodgkin’s
lymphoma. The aim of this long-term follow-up study was to determine the incidence, the time
free of second tumors, and risk factors for developing secondary cancer in a homogeneous
group of patients with non-Hodgkin’s lymphoma.
Design and Methods
We evaluated a total of 563 patients with indolent non-Hodgkin’s lymphoma enrolled in Gruppo
Italiano Studio Linfomi trials from 1988 to 2003.
Results
After a median follow-up of 62 months, 39 patients (6.9%) developed secondary cancer: 12
myelodysplastic syndromes/acute myeloid leukemia, and 27 solid tumors. The overall stan-
dardized incidence ratio of secondary malignancy in patients with non-Hodgkin’s lymphoma
was higher than the risk of malignancy in the general population. The standardized incidence
ratio was elevated in male patients and in patients under 65 years old at first treatment.
Overall, the cumulative incidence of secondary cancer at 12 years was 10.5%, after correction
in a competing-risk model. Univariate and multivariate Cox regression analyses showed that
older age at the time of diagnosis, male sex, and fludarabine-containing therapy had significant
negative impacts on the time free of second tumors.
Conclusions
We have identified subgroups of non-Hodgkin's lymphoma patients with increased standard-
ized incidence ratios of secondary malignancy and variables that have a negative impact on
the time free of second tumors. This information could help physicians to select the most appro-
priate treatments. Finally, taking into account the possible occurrence of secondary neoplasia,
long-term monitoring must be considered.
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lymphoma, treatment.
Citation: Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda
G, Lazzaro A, Gobbi P, Stelitano C, Morabito F, Quarta G, and Brugiatelli M. Secondary malig-
nancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study
Haematologica 2008 Mar; 93(3):398-404. doi:10.3324/haematol.12120
©2008 Ferrata Storti Foundation. This is an open-access paper.
| 398 | haematologica | 2008; 93(3) 
Secondary malignancies after NHL
haematologica | 2008; 93(3) | 399 |
Introduction
Given the now successful treatment of Hodgkin's lym-
phoma, secondary cancers and late sequelae of this
malignancy have been studied extensively.1 In contrast,
relatively little information on secondary cancers is avail-
able for non-Hodgkin’s lymphomas (NHL) because treat-
ments for NHL have been less effective compared to
those for Hodgkin’s lymphoma. However, evolving ther-
apies, such as monoclonal antibodies, have improved the
prognosis of NHL2-5 and increased the long-term survival
of patients. 
Several studies6-11 (but not all)12-14 have reported an
increased overall risk of secondary cancer after treat-
ments for NHL. The increased risk pertained especial-
ly8,9,11,13 or solely14 to patients who were relatively young
at the time of the first treatment. This elevated risk was
due mainly to high incidences of myelodysplastic syn-
drome/acute myeloid leukemia (MDS/AML)9,11,13 and
solid tumors, including those found in lung, bladder, and
the colon.11,13
Few of these studies have reported cancer risk beyond
10 years after treatment, and none has focused on indo-
lent lymphoma. Furthermore, the majority of studies are
population-based. Although these investigations have
analyzed thousands of patients, they utilize cancer reg-
istry databases that typically contain little information on
clinical baseline characteristics or chemotherapy regi-
mens. In the present study, we analyzed a large cohort of
patients with indolent lymphoma who participated in
clinical trials at Gruppo Italiano Studio Linfomi (GISL) cen-
ters. The aim of this long-term follow-up study was to
determine the incidence rate and identify risk factors for
the development of secondary cancer in a homogeneous
group of patients. The clinical characteristics of these
patients as well as first-line and subsequent treatments
were recorded at the times of diagnosis and recurrence.
Design and Methods
Patients
The GISL maintains a database on the treatment and
follow-up of all NHL patients enrolled in clinical trials.
Data managers at participating centers routinely update
the central GISL database every 3-6 months throughout
the trials and every 6-12 months during follow-up. The
data managers fill out standardized forms that include
information on patients’ characteristics, laboratory
parameters, treatments, outcome, late toxicity, and the
occurrence of second cancers. The data managers
describe the observed secondary cancers, which are sub-
sequently codified in Modena. When necessary, addi-
tional information can be requested from the investiga-
tors. Eligibility criteria for this study were: i) patients
with previously untreated NHL with a histologically con-
firmed diagnosis of follicular lymphoma (FL), small lym-
phocytic lymphoma (SLL), or marginal zone B-cell lym-
phoma (MZL), either nodular and extranodular or
splenic; (ii) availability of data on clinical characteristics,
laboratory parameters, treatments (as reported in Tables
1 and 2), outcome, and the occurrence of second cancers;
(iii) availability of follow-up data for more than 6 months
after diagnosis.
Between 1988 and 2003, 625 patients with indolent
NHL were enrolled in a number of GISL trials. Of these
patients, 62 (10%) were excluded: 40 because they did
not complete the planned chemotherapy and were
immediately lost during the follow-up period, and 22
because of insufficient data (more than 25% of the data
missing). Thus, for the purposes of this study, we identi-
fied 563 patients with FL, SLL and MZL. The treatment
regimens utilized and the number of patients in each trial
are summarized in Table 1. Briefly, patients in groups 1-
8 were treated with one of the following regimens: chlo-
rambucil +/- prednisone,15 high-dose chlorambucil +
prednisone,16 high-dose chlorambucil prednisone + epi-
doxorubicin,16 fludarabine + cyclophosphamide,17
methylprednisolone + cyclophosphamide + epidoxoru-
bicin + etoposide + cytarabine + bleomycin + vincristine
+ methotrexate (ProMECE-CytaBOM),18 bleomycin +
epidoxorubicin + cyclophosphamide + vincristine +
prednisone (BACOP),19 BACOP + fludarabine + mitox-
antrone + dexamethasone,20 or BACOP + fludarabine +
rituximab.21
All of the GISL trials complied with the requirements
of the Declaration of Helsinki and its amendments and
were conducted in accordance with Good Clinical
Practice guidelines. The protocols were approved by the
institutional review board at each participating center.
Written informed consent was obtained from all patients.
Approval for the present study was obtained from the
review board of the GISL. Upon completion of
chemotherapy, involved-field radiotherapy was allowed
at the treating physician’s discretion to irradiate residual
masses or the sites of previous bulky or extranodal dis-
ease. According to study protocols, the radiotherapy
dose was 30-40 Gy. 
Statistical methods
Follow-up began at the end of the first treatment for
NHL and ended at the date of death, the date of last fol-
low-up evaluation, the date of diagnosis of secondary
cancer, or the end of the study (April 30, 2007), whichev-
er occurred first. Secondary cancers were classified by
site in accordance with the oncology section of the
International Classification of Disease.22 Individuals who
developed malignancies within 6 months of the diagno-
sis of NHL or had a primary cancer other than NHL were
excluded from this analysis. 
The primary aims of this research were to determine
the incidence of secondary malignancies, the time free of
second tumors, and risk factors for the development of
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secondary cancer. The incidence of secondary neoplasia
per person/year in the study population was compared
with the incidence of malignancy in the Italian popula-
tion, utilizing age-, sex-, and calendar period-specific
incidence rates derived from the Italian Institute of
Health (ISS, Istituto Superiore di Sanità).23 The standardized
incidence ratio (SIR) was calculated from the ratio
between the observed and expected numbers of cancers;
95% confidence intervals (95% CI) were based on the
assumption that the observed numbers of secondary can-
cers were distributed as Poisson variables.24 Absolute
excess risk (AER) of secondary cancer was calculated by
subtracting the expected from the observed cases and
dividing by the number of person-years at risk. AER was
expressed per 100 person-years. Cumulative incidences
were estimated in the competing-risk model, with death
from any cause as the competing event.25 The time free of
second tumors was measured from the end of the first
treatment to the last follow-up or to the date of diagno-
sis of a second tumor and was calculated using a Kaplan-
Meier estimate. The Cox proportional-hazards model
was used to quantify the effects of different treatments
on the risk of secondary cancer within the patient group,
adjusting for demographic confounders and stratifying
by type of histology (follicular or non-follicular lym-
phoma), as opposed to the person-years analysis in
which risk was compared with that in the general popu-
lation. The proportional-hazard assumption of risk was
checked by graphical analysis of Schoenfeld residuals,
and the functional form of co-variates was checked by
analysis of Martingale residuals.26 The level of statistical
significance for all tests was set at two-sided p<0.05.
Over-optimism and calibration of the model was com-
puted over 250 bootstrap replications by means of
Harrell’s methods.27 All analyses were performed with
the Stata 8.2/SE package.28
Results
Patients’ characteristics
A total of 563 patients with indolent NHL met the
defined eligibility criteria and were included in this
analysis. The case record forms had good overall qual-
ity; only 14% of the forms lacked data. The 5-year
overall survival rates were 82%, 65%, and 85% for
patients with FL, SLL, and MZL, respectively, with a
median follow-up of 62 months (range, 3-212 months)
for all patients and of 70 months for living patients. The
number of patients and follow-up times comprised
2858 person-years of risk for a secondary tumor. The
median age at diagnosis was 60 years (range, 22-84)
and 51% (n=289) of patients were male. All patients
were treated with chemotherapy, either alone (88%) or
in combination with radiotherapy (12%). The patients’
characteristics and treatments are summarized in
Tables 1 and 2.
Secondary malignancies
During the follow-up, 39 patients (6.9%) developed a
second cancer. A total of 196 patients died, 19 were lost
during the follow-up period, and the remaining 348
patients (15 with secondary cancer) survived to the end
of the study period. The most common causes of death
were progressive disease (56%), secondary cancer
(13%), cardiopathy (12%), and infection (5%). No
patients developed a third cancer during the follow-up
period. Twelve of the 39 patients with secondary can-
cers developed MDS/AML, and 27 developed solid
tumors including lung cancer (n=8), gastro-intestinal
cancer (n=7), and other types of cancer (n=12) (Table 3).
We did not observe cases of secondary Hodgkin’s lym-
phoma or NHL. However, biopsies with histological
examination were not performed in relapsed cases, and
further occurrences were usually considered relapses.
Thus, the incidence of Hodgkin’s lymphoma and of
new or transformed NHL could be underestimated.
Fourteen of the 39 second malignancies occurred after
additional treatments for progressive or recurrent dis-
ease. The median time from diagnosis of indolent NHL
to diagnosis of a solid tumor was 52 months (range, 16-
164 months), and that to diagnosis of MDS/AML was
25 months (range, 6-168 months).
Table 1. Treatment utilized in the 563 patients with indolent lym-
phoma.
Characteristics N. of % of  Person-years
patients patients at risk
563 100 2858
Chemotherapy regimens
Chl ± P 72 13 445
HDChl-P 82 14 354
HDChl-PE 82 14 365
FC 38 7 74
ProMECE-CytaBOM 34 6 316
BACOP 88 16 676
BACOP/FND 139 25 368
BACOP/FR 28 5 60
Chemotherapy containing:
Alkylating (Alk) 154 28 798
Alk + Anthracycline 204 36 1357
Alk + Anthracycline + Fludarabine 205 36 703
Radiotherapy
No 493 88 2354
Yes 70 12 504
More than one line of treatment
No 307 54 1488
Yes 256 46 1370
Chl ± P: chlorambucil ± prednisone; HDChl-P: high dose Chl-prednisone;
HDChl-PE: HDChl-P plus Epidoxorubicin; FC: fludarabine, cyclophos-
phamide; ProMECE-CytaBOM: methylprednisolone, cyclophosphamide, epi-
doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate; BACOP:
bleomycin, epidoxorubicin, cyclophosphamide, vincristine, prednisone;
BACOP/FND: BACOP plus fludarabine, mitoxantrone, dexamethasone;
BACOP/FR: BACOP plus fludarabine, rituximab. 
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Incidence of secondary malignancy
The overall risk of secondary malignancy in patients
with indolent NHL was higher than the risk of malig-
nancy in the general Italian population (SIR 1.9; 95%
CI: 1.4-2.7). As shown in Table 4, the overall incidence
of malignancy was highest in male patients (SIR 2.72;
95% CI: 1.76-4.02, p=0.016), and in patients who were
under 65 years old at the time of their first treatment
(SIR 2.66; 95% CI: 1.69-4.0, p=0.037). In the subgroup
with follicular histology (SIR 2.58; 95% CI: 1.58-3.98),
and in patients treated with radiotherapy (SIR 2.48;
95% CI: 0.91-5.40), the SIR were increased, but not to
a statistically significant extent (p>0.05). 
The overall risk of secondary malignancy was
increased for each treatment modality, but achieved
marginal significance (p=0.074) for treatments contain-
ing fludarabine. Interestingly, the increase in risk of sec-
ondary malignancy observed in patients treated in
2000-2003 coincided with the introduction of fludara-
bine in GISL chemotherapy regimens (Table 4). 
The risk of secondary malignancy relative to age at
diagnosis of the second cancer is shown in Table 5. An
increased risk of secondary cancer was detected in the
cohort groups aged 45-54 (SIR 4.91; 95% CI: 2.2-10.1,
AER 0.78) and those aged 55-64 (SIR 3.41; 95% CI:
1.98-5.87, AER 1.05). The cumulative incidences of sec-
ondary malignancy, including MDS/AML, were 6.6%,
9.5%, and 15.3% at 5, 8, and 12 years, respectively,
Table 2. Descriptive characteristics of the 563 patients with indo-
lent lymphoma.
Characteristics N. of % of Person-years
patients patients at risk  
Total 563 100 2858
Age at diagnosis, years
22-50 133 24 912
51-60 151 27 775
61-70 217 38 966
71-84 62 11 205
Gender
Female 274 49 1558
Male 289 51 1300
Histology
Follicular 296 53 1671
Small lymphocytic lymphoma 224 40 1092
Marginal zone* 43 7 95
Period of first treatment
1988-1994 187 33 1407
1995-1999 181 32 904
2000-2003 195 35 547
FLIPI score#
0-2 341 66 1977
3-5 178 34 646
Bulky disease
No 513 91 2688
Yes 50 9 170
B-Symptoms
No 476 85 2478
Yes 87 15 380
Extranodal sites of disease
0-1 399 71 2204
> 1 164 29 654
Follow-up
5 years or less 279 581
more than 5 years 284 2277
more than 10 years 78 929
*Splenic or nodal and extanodal marginal zone B-cell lymphoma; #missing data
for 44 of 563 cases (7.8%).
Table 3. Cases and sites of secondary cancer.
Second tumor ICD-9 code N. of % of Person-years
patients patients at risk
MDS/AML 238.72-238 12 2.1 40
73-205-208
Lung 162 8 1.4 51
Digestive tract 151-153- 7 1.2 36
154-155-157
Breast 174 2 0.4 14
Larynx 161 2 0.4 2
Prostate 185 2 0.4 11
Bladder 188 2 0.4 12
Ovaries 183 1 0.2 2
Adrenocortical glands 194 1 0.2 3
Melanoma 172 2 0.4 5
Total n. of tumors 39 6.9 2858
No second tumors 524 93.1 2682
ICD-9: International Classification of Diseases 9th Edition.
http://www.cdc.gov/nchs/icd9.htm
Table 4. Standardized incidence risk and absolute excess risk of
second cancer analyzed according to demographics and treat-
ment (34 cases out of 39)*.
Factor Observed Expected SIR (95%CI) AER p°
Gender
Female 9 8.2 1.10 (0.50-2.10) +0.05 0.016
Male 25 9.2 2.72 (1.76-4.02) +1.01
Age at first treatment
<65 23 8.6 2.66 (1.69-4.00) +0.68 0.037
65+ 11 8.7 1.26 (0.63-2.26) +0.32
Histology
FL 20 7.76 2.58 (1.58-3.98) +0.73 0.251
SLL 13 8.70 1.49 (0.80-2.55) +0.39
MZL 1 0.87 1.15 (0.03-6.43) +0.14
Chemotherapy-containing
Alkylating (Alk) 10 6.50 1.54 (0.74-2.83) +0.44 0.074
Alk+anthracycline 11 7.02 1.57 (0.78-2.80) +0.29
Alk+anthracycline+ 13 3.81 3.41 (1.81-5.83) +1.31
fludarabine
Radiotherapy
No 28 14.9 1.88 (1.25-2.71) +0.54 >0.50
Yes 6 2.40 2.48 (0.91-5.40) +0.72
Period of first treatment 
1988-1994 15 8.66 1.73 (0.97-2.86) +0.45 >0.50
1995-1999 10 5.40 1.85 (0.89-3.40) +0.51
2000-2003 9 3.26 2.76 (1.26-5.23) +1.05
SIR: standardized incidence risk. AER: absolute excess risk. *Five MDS cases
were excluded. °Chi-squared test for unequal SIR.29
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estimated using the Kaplan-Meier method. After cor-
rection in a competing-risk model by Gooley’s method,
the cumulative incidences of secondary malignancy
were reduced to 5.5%, 6.5%, and 10.5% at 5, 8, and 12
years, respectively (Figure 1). 
Risk factors for developing a secondary malignancy
The probabilities of remaining free of a second tumor
estimated at 5, 8 and 12 years were 93%, 90% and
85%, respectively. In a univariate Cox regression
model, the factors that had a significant negative
impact (p<0.05) on time free of a second tumor were
older age at first treatment (a hazard ratio (HR) incre-
ment of 1.9 was associated with each 10-year incre-
ment above the median age), male sex, and fludara-
bine-containing therapy. Factors that did not signifi-
cantly influence time free of a second tumor included
the Follicular Lymphoma International Prognostic
Index (FLIPI) score, which takes into account elevated
lactate dehydrogenase levels, the presence of more
than four nodal sites of disease, clinical stage III-IV dis-
ease, age >60 years, and other baseline characteristics
of the patient such as bulky disease, more than one
extranodal site, and B-symptoms. Thus, we did not
consider these factors as potential confounders. 
In order to evaluate the impacts of variables with sig-
nificant influences further, we performed a Cox regres-
sion analysis stratified by histology, utilizing age at first
treatment in a continuous form scaled by the median
age of the population (60 years). This multivariate
analysis confirmed the prognostic values of age, male
gender, and fludarabine-based treatment, as demon-
strated by statistically significant hazard ratios (Table
6). The model showed good performance, with a
shrinkage factor of 0.994 and an unbiased discriminat-
ing power (C-statistic of 0.723; 95% CI: 0.863-0.604)
over 250 bootstrap replications. Furthermore, the
regression coefficient showed an acceptable shrinkage
factor (>0.9), considering the small number of observed
events. 
In a separate analysis, the univariate Cox regression
analysis of time free of second tumor indicated that
MDS/AML was detected mainly in male patients (HR:
6.2, p=0.02) and in patients older than 60 years (HR:
5.7, p=0.026). Treatments that included fludarabine did
not appear to be associated with the development of
MDS/AML. The development of solid tumors did,
however, appear to be associated with male gender
(HR: 4.04, p=0.002) and to fludarabine containing treat-
ments (HR: 3.1, p=0.013). Lung cancer was principally
associated with male gender (HR: 12.5, p=0.021).
Discussion
In the present study, we analyzed a large and homo-
geneous cohort of patients with indolent lymphoma
who participated in clinical trials at GISL centers. These
trials spanned more than 15 years. Data on patients’
demographics, baseline characteristics, histology, clini-
cal stage, and treatments were recorded prospectively
in the GISL database at the times of diagnosis, recur-
rence, and follow-up evaluation. However, results must
be interpreted cautiously because they could be biased
by the retrospective nature of the study. As data man-
agers at participating centers were not urged to specifi-
Table 5. Standardized incidence risk (SIR) and absolute excess risk
(AER) of second cancer (34 cases out of 39) related to age-, and
calendar period- specific incidence. Data derived from the ISS*
database, by ICD-9 coding from 140 to 208. 
Cohort Person-yrs Observed Expected SIR 95% C.I. AER
age failures failures
20-44 363 0 0.04 - - -
45-54 615 6 1.22 4.91 2.20-10.9 +0.78
55-64 878 13 3.81 3.41 1.98-5.87 +1.05
65-74 885 12 9.64 1.24 0.71-2.19 +0.27
75+ 170 3 2.8 1.06 0.34-3.28 +0.09
Total 2911 34 17.6 1.94 1.38-2.71 +0.56
*ISS: Istituto Superiore di Sanità (Italian Institute of Health).
Table 6. Cox regression model stratified by type of histology with
bootstrap validation. 
Covariate Coefficient SE HR p Bootstrap validation (B=250)
Unbiased Coeff. Shrinkage
Age* 0.073 0.019 2.08* <0.001 0.067 0.93
Gender M** 1.530 0.394 4.62 <0.001 1.392 0.91
Fludarabine use** 0.957 0.429 2.60 0.026 0.895 0.94
C-statistics 0.757 (95%CI 0.685-0.828) 0.723 (95%CI 0.604-0.843)
Shrinkage factor (model) 0.944
*Age in continuous form scaled at the median (60 years old), HR referred to
increasing age by 10 years; **gender code: F=0, M=1; fludarabine use code: not
used=0, used=1.
Figure 1. Cumulative incidence of second cancer by the Kaplan-
Meier (CI - KM) estimation compared to cumulative incidence
according to Gooley (CI - Gooley). 
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cally report on secondary cancer, our results could
slightly underestimate the risk of secondary cancer.
Overall, the risk of secondary malignancy, excluding
MDS, was only slightly higher than the risk of malig-
nancy observed in the general population. However,
including MDS/AML, 39 secondary tumors were
observed and the 12-year cumulative incidence rate,
after correction in a competing-risk model, was 10.5%. 
MDS/AML and lung cancer, mainly occurring in men,
accounted for more than 50% of the total number of
secondary malignancies. The risk of a second tumor
was increased significantly in the male population. Our
results also show an increased risk of malignancy in
patients 45-64 years old; the risk in patients older than
65 matched that in the general population. The overall
relative risk of secondary malignancy was increased for
each treatment modality but was particularly elevated,
although with marginal statistical significance, in
patients treated with fludarabine-based chemotherapy.
Surprisingly, treatments that included fludarabine did
not appear to be associated with the development of
MDS/AML.
Factors that had a significant negative impact on time
free from a second tumor included age at first treat-
ment, male sex, and fludarabine-containing therapy. A
Cox multivariate regression analysis stratified by his-
tology and utilizing age in a continuous form scaled by
the median confirmed the prognostic risk factors of age
at the time of diagnosis, male gender, and fludarabine-
based treatment. 
In conclusion, based on a retrospective analysis, we
have identified subgroups of patients with increased
SIR and variables that have a negative impact on time
free from a second tumor. If considered together with
traditional prognostic factors and possible side effects
of treatment, this information can help physicians to
determine the most appropriate treatments. Finally,
taking in to account the possible occurrence of second-
ary neoplasia, long-term monitoring should be consid-
ered.
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